Kathleen C.
- Country
- Belgium
- Department
- Department of Nephrology
Research Overview
- Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
- Evaluation of Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sibeprenlimab in Patients with Immunoglobulin A Nephropathy
Data & Insights
Has run more than one trial at 137 of 439 partner sites.
Specializations
Primary Nephropathies
The investigator specializes in treating Immunoglobulin A Nephropathy (IgAN), conducting research on various therapeutic approaches including novel treatments like sibeprenlimab, ravulizumab, and povetacicept.
- IgA Nephropathy management
- Proteinuria reduction strategies
- Kidney function preservation
Additional focus on complement-mediated kidney diseases including investigations of iptacopan and related compounds.
Rare Kidney Disorders
Expertise in treating rare conditions such as APOL1-mediated Proteinuric Kidney Disease (AMKD) and atypical Hemolytic Uremic Syndrome (aHUS).
- C3 Glomerulopathy treatment
- Immune-complex membranoproliferative glomerulonephritis
- Genetic kidney disorders
Research includes innovative therapies like crovalimab and pegcetacoplan for rare nephropathies.
Chronic Kidney Disease
Focused on developing treatments for non-diabetic chronic kidney disease with particular attention to novel therapeutic approaches.
- Protein excretion reduction
- Kidney disease progression
- Standard of care optimization
Investigates treatments including finerenone and BAY3283142 for chronic kidney conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.